| Patient | Jesse Owens |
|---|---|
| Date of birth | 1913-09-12 |
| Identifiers | MRN HR-ML042-SYN-TD; SSN (made up) 000-42-8319 |
| Document date | 1979-05-26 |
| Author | Clarence Whitfield-Arroyo, MD |
| Custodian | St. Posthumous Health Center |
Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.
Diagnosis visit: staging and biopsy results, the tumor board plan, and the thoracic oncology consultation. [S]
Mr. Owens returns two weeks after the screening CT. PET-CT three days after the scan showed the 2.9 cm left upper lobe nodule and a left interlobar node to be active, with nothing in the mediastinum or elsewhere, and brain MRI the next day was clear. Endobronchial ultrasound a week ago found adenocarcinoma in the interlobar node, with four other node stations negative. PD-L1 is 40 percent, and tissue sequencing, back yesterday, shows a KRAS G12C mutation and no EGFR, ALK or other targetable alteration. The thoracic tumor board reviewed him five days ago. He had pulmonary function tests this morning and saw Dr. Halvorsen-Pierce at midday. He still has his usual morning cough, no breathlessness, and has lost no weight. He is still smoking a pack a day and now wants to stop: the scan has convinced him. He has had no thoughts of self-harm. [S]
| Element | Detail |
|---|---|
| Diagnosis | Adenocarcinoma of the left upper lobe, cT1c N1 M0, stage IIB; resectable |
| Procedures since the first visit | PET-CT, brain MRI, endobronchial ultrasound with systematic node sampling, pulmonary function tests |
| Biomarkers | PD-L1 40 percent; KRAS G12C; no EGFR, ALK, ROS1, BRAF, MET exon 14, RET, NTRK or HER2 alteration |
| Tumor board | Three cycles of nivolumab with platinum chemotherapy, restaging, then lobectomy |
| His questions | Whether it can be cured; why surgery is not first; whether stopping smoking now makes any difference; whether he can keep speaking at schools |
| System | Result | Finding |
|---|---|---|
| Constitutional | Negative | No weight loss, fever or night sweats; weight 76.6 kg |
| Respiratory | Positive | Usual morning cough with a little clear sputum; no breathlessness or hemoptysis |
| Cardiovascular | Negative | No chest pain or leg swelling |
| Musculoskeletal | Negative | No bone pain |
| Neurological | Negative | No headache, weakness or numbness |
| Psychiatric | Positive | Worried but hopeful; PHQ-9 6, GAD-7 7; no thoughts of self-harm |
6 systems reviewed. [S]
| Medication | Frequency | Route | Dates | Status | Evidence |
|---|---|---|---|---|---|
| Varenicline 0.5 mg oral tablet: one tablet daily for three days, then one tablet twice daily for four days (starting week), with a quit date on day 8 | 0.5 mg daily on days 1 to 3, then 0.5 mg twice daily on days 4 to 7 | Oral route | 1979-05-26 to 1979-06-01 | completed | S |
| Folic acid 1 mg oral tablet, one tablet daily from one week before the first pemetrexed dose until three weeks after the last | One tablet daily | Oral route | 1979-05-26 to 1979-08-05 | completed | S |
| Cyanocobalamin (vitamin B12) 1000 mcg intramuscular injection, one dose a week before the first pemetrexed dose (repeat every nine weeks while on pemetrexed) | 1000 mcg once; a second dose was not due before pemetrexed ended | Intramuscular route | 1979-05-26 to 1979-05-26 | completed | S |
| Allergy | Reaction | Status | Evidence |
|---|---|---|---|
| No known allergy | active | S |
| Date | Measure | Value | Unit | Provenance |
|---|---|---|---|---|
| 1979-05-26 | Body height | 178 | cm | S |
| 1979-05-26 | Body weight | 76.6 | kg | S |
| 1979-05-26 | Body mass index (BMI) [Ratio] | 24.2 | kg/m2 | S |
| 1979-05-26 | Systolic blood pressure | 130 | mm[Hg] | S |
| 1979-05-26 | Diastolic blood pressure | 80 | mm[Hg] | S |
| 1979-05-26 | Heart rate | 80 | /min | S |
| 1979-05-26 | Respiratory rate | 16 | /min | S |
| 1979-05-26 | Body temperature | 36.6 | Cel | S |
| 1979-05-26 | Oxygen saturation in Arterial blood by Pulse oximetry | 95 | % | S |
| Date | Measure | Value | Unit | Reference range | Flag | Provenance |
|---|---|---|---|---|---|---|
| 1979-05-26 | Hemoglobin [Mass/volume] in Blood | 14.9 | g/dL | 13.5-17.5 g/dL | Normal | S |
| 1979-05-26 | Leukocytes [#/volume] in Blood by Automated count | 8.1 | 10*3/uL | 4-11 10*3/uL | Normal | S |
| 1979-05-26 | Neutrophils [#/volume] in Blood by Automated count | 5.2 | 10*3/uL | 1.5-7.7 10*3/uL | Normal | S |
| 1979-05-26 | Platelets [#/volume] in Blood by Automated count | 258 | 10*3/uL | 150-400 10*3/uL | Normal | S |
| 1979-05-26 | Creatinine [Mass/volume] in Serum or Plasma | 1 | mg/dL | 0.7-1.3 mg/dL | Normal | S |
| 1979-05-26 | Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 1974)/1.73 sq M | 84 | mL/min/{1.73_m2} | >=60 mL/min/1.73 m² | Normal | S |
| 1979-05-26 | Glucose [Mass/volume] in Serum or Plasma | 97 | mg/dL | 70-99 mg/dL | Normal | S |
| 1979-05-26 | Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 23 | U/L | 7-55 U/L | Normal | S |
| 1979-05-26 | Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 22 | U/L | 8-48 U/L | Normal | S |
| 1979-05-26 | Bilirubin.total [Mass/volume] in Serum or Plasma | 0.6 | mg/dL | 0.1-1.2 mg/dL | Normal | S |
| 1979-05-26 | Thyrotropin [Units/volume] in Serum or Plasma | 1.9 | m[IU]/L | 0.4-4 mIU/L | Normal | S |
| 1979-05-26 | Thyroxine (T4) free [Mass/volume] in Serum or Plasma | 1.2 | ng/dL | 0.8-1.8 ng/dL | Normal | S |
| 1979-05-26 | Cortisol [Mass/volume] in Serum or Plasma | 13.8 | ug/dL | Morning (8 a.m.) reference interval | Normal | S |
| 1979-05-26 | FEV1 | 2.71 | L | Lower limit of normal for his age and height (GLI 1965) | Normal | S |
| 1979-05-26 | FEV1 measured/predicted | 86 | % | >=80% | Normal | S |
| 1979-05-26 | FEV1/FVC | 0.73 | {ratio} | Below 0.70 after bronchodilator indicates airflow obstruction | Normal | S |
| 1979-05-26 | Diffusion capacity.carbon monoxide | 23.6 | mL/min/mm[Hg] | Lower limit of normal for his age and height; predicted 27.4 | Normal | S |
| 1979-05-26 | Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] | 6 | {score} | S | ||
| 1979-05-26 | Generalized anxiety disorder 7 item (GAD-7) total score [Reported.PHQ] | 7 | {score} | S |
Vital signs recorded on 1979-05-26; see the Vital Signs section. [S]
| System | Finding |
|---|---|
| General | Well and upright; weight 76.6 kg; blood pressure 130/80, pulse 80; oxygen saturation 95 percent |
| Lymph nodes | No supraclavicular or cervical nodes |
| Respiratory | Breath sounds equal; scattered early-morning rhonchi that clear with a cough; no wheeze |
| Cardiovascular | Regular rhythm; no murmur; no edema |
| Extremities | No clubbing |
| Psychiatric | Attentive, asks direct questions and writes the answers down |
| Problem | Clinical status | Verification | Code | Provenance |
|---|---|---|---|---|
| Solid, spiculated 2.9 cm nodule in the left upper lobe with an enlarged (1.6 cm) left hilar lymph node on today's low-dose screening CT, Lung-RADS 4X (very suspicious); no symptoms of lung cancer. PET-CT, tissue diagnosis and thoracic oncology review booked | resolved | confirmed | R91.1 | S — Synthetic presenting screening finding in a long-term smoker. Superseded by the diagnosis at the second visit. |
| Adenocarcinoma of the left upper lobe of the lung, cT1c N1 M0, stage IIB (AJCC 8th edition), resectable: 2.9 cm primary with a positive left interlobar (11L) node on EBUS; mediastinal nodes 4R, 4L and 7 negative; no metastases on PET-CT or brain MRI. PD-L1 tumor proportion score 40 percent (22C3); KRAS G12C mutation; no EGFR, ALK, ROS1, BRAF, MET exon 14, RET, NTRK or HER2 alteration | active | confirmed | C34.12 | S — Synthetic histology, stage and biomarkers linked to his documented adenocarcinoma of the left lung; in the modern episode it is found by screening while still resectable. |
| Nicotine dependence, cigarettes: a pack a day for 35 years (35 pack-years); smokes his first cigarette within 30 minutes of waking; two attempts to stop, each lasting a few weeks without medicine | active | confirmed | F17.210 | S — Synthetic modern entry linked to his documented smoking; superseded at the visit after surgery by nicotine dependence in early remission. |
Protocol monitoring: items the monitoring protocol calls for at this visit. [S]
| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Laboratory | Tissue diagnosis, PD-L1 and comprehensive biomarker testing | At diagnosis, before any systemic therapy; EGFR and ALK must be negative before chemoimmunotherapy | Up to date | Adenocarcinoma (TTF-1 positive); PD-L1 40 percent; KRAS G12C; EGFR, ALK, ROS1, BRAF, MET exon 14, RET, NTRK and HER2 negative on tissue and plasma |
| Imaging | Staging FDG PET-CT and brain MRI | At diagnosis for stage II or higher | Up to date | No mediastinal or distant disease on PET-CT; brain MRI clear |
| Examination | Invasive mediastinal staging | Before treatment when a central tumor or a positive hilar node is present (ACCP) | Up to date | EBUS: 11L positive; 4R, 4L, 7 and 10L negative |
| Referral | Thoracic multidisciplinary tumor board and thoracic surgery | Before treatment of every potentially resectable cancer | Up to date | Tumor board five days ago; thoracic surgery review booked after cycle 2 |
| Imaging | Pulmonary function: spirometry and DLCO with predicted postoperative values | Before lung resection | Completed today | FEV1 2.71 L (86 percent), FEV1/FVC 0.73, DLCO 23.6 (86 percent); predicted postoperative FEV1 and DLCO 63 percent: low risk, no exercise test needed |
| Laboratory | Immune-related adverse event laboratory panel: TSH, free T4, liver tests, creatinine and glucose | Baseline, then before each immunotherapy infusion | Completed today | TSH 1.9, free T4 1.2; ALT 23, AST 22, bilirubin 0.6; creatinine 1.0, eGFR 84; glucose 97 |
| Laboratory | Morning cortisol | Baseline and before each immunotherapy infusion (CMID); for symptoms | Completed today | 13.8 mcg/dL at 8 a.m. |
| Laboratory | Blood count with neutrophils and platelets | Baseline, then before each chemotherapy cycle | Completed today | Hemoglobin 14.9, white cells 8.1, neutrophils 5.2, platelets 258 |
| Laboratory | Hepatitis B, hepatitis C and HIV screening | Before systemic cancer therapy | Completed today | Drawn today; results to the oncology team before cycle 1 |
| Self-management | Tobacco use and cessation treatment | Every visit | Completed today | Still smoking a pack a day; ready to quit; varenicline started with a quit date of day 1 of cycle 1; quitline enrolled |
| Survey | Distress and depression screening | Every visit; PHQ-9 and GAD-7 at diagnosis and at treatment transitions | Completed today | PHQ-9 6 (item 9 scored 0), GAD-7 7; worried, supported at home |
| Examination | Dyspnea and cough assessment | Every visit | Completed today | Usual morning cough; no breathlessness |
| Self-management | Pulmonary rehabilitation (prehabilitation) | Before and after lung resection | Referred | Twice-weekly program from next week, alongside chemotherapy |
| Referral | Specialist palliative care | Early, for advanced or high-symptom-burden cancer | Not indicated | Resectable cancer treated with curative intent and no symptom burden; symptoms and distress are screened at each visit and referral will follow if needs arise |
| Imaging | Surveillance CT; routine brain MRI; PET-CT and ctDNA for surveillance | After curative treatment | Not indicated | Not yet applicable; PET-CT and circulating markers are not used for surveillance |
| Self-management | Equity: navigation and time to treatment | Each step of the pathway | Completed today | Diagnosis and plan 15 days after the screening CT; treatment starts in eight days; nurse navigator and transport help in place |
Goal progress:
Immunizations given today: Pneumococcal conjugate vaccine PCV20, before chemoimmunotherapy [S]
Guideline basis: CMID: Clinical Monitoring Intelligence Database, lung cancer monograph (2026); NCCN Clinical Practice Guidelines in Oncology: Non-Small Cell Lung Cancer (2026); Silvestri GA, et al. Methods for staging non-small cell lung cancer: Diagnosis and management of lung cancer, 3rd ed: ACCP evidence-based clinical practice guidelines. Chest 2013;143(5 Suppl):e211S-e250S (PMID 23649440) (2013); Brunelli A, et al. Physiologic evaluation of the patient with lung cancer being considered for resectional surgery: ACCP evidence-based clinical practice guidelines. Chest 2013;143(5 Suppl):e166S-e190S (PMID 23649437) (2013); Forde PM, et al. Neoadjuvant Nivolumab plus Chemotherapy in Resectable Lung Cancer (CheckMate 816). N Engl J Med 2022;386(21):1973-1985 (PMID 35403841) (2022); Schneider BJ, et al. Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: ASCO Guideline Update. J Clin Oncol 2021;39(36):4073-4126 (PMID 34724392) (2021); Tobacco Smoking Cessation in Adults, Including Pregnant Persons: Interventions (2021)
Follow-up: Cycle 1 in eight days, on his quit date. Visit at cycle 2. Call the 24-hour oncology line for fever, breathlessness, a new cough, diarrhea, rash, yellow eyes or severe tiredness. Next scheduled visit 1979-06-24: day 1 of cycle 2 of nivolumab with carboplatin and pemetrexed: toxicity, immune-related adverse event monitoring, smoking abstinence and prehabilitation. [S]